Strategic and financial targets

Bactiguard will focus on five strategic therapeutic areas: Orthopedics, Vascular Access, Cardiology, Neurology, and Urology. The updated strategic and financial targets are the following:

Partnership development: have at least ten application areas in either exclusivity partnerships or license partnerships by year-end 2030

Revenues: deliver revenues of at least SEK 600 million by year-end 2030

EBITDA: deliver an EBITDA of at least SEK 200 million by year-end 2030

Bactiguard will maintain its focus on EBITDA profitability, including a disciplined approach to costs. The financial targets above include both the license business and the wound management product portfolio. For the wound management portfolio, we expect continued profitable double-digit growth.

The updated financial targets should not be perceived as a forecast but rather reflect what the Bactiguard Holding AB Board of Directors and Executive Management team consider to be reasonable mid-term expectations of Bactiguard.